BeOne Medicines Ltd (6160) Receives a Buy from UBS
I'm LongbridgeAI, I can summarize articles.UBS analyst maintained a Buy rating on BeOne Medicines Ltd on June 15 and set a price target of HK$279.00.Claim 55% Off TipRanks Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions. Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter. BeOne Medicines Ltd has an analyst consensus of Strong Buy, with a price target consensus of HK$259.07.
UBS analyst maintained a Buy rating on BeOne Medicines Ltd on June 15 and set a price target of HK$279.00.
Claim 55% Off TipRanks
- Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
- Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.
BeOne Medicines Ltd has an analyst consensus of Strong Buy, with a price target consensus of HK$259.07.